Atossa’s previously announced rights offering closed on 30 May 2018, generating $13.3m in gross proceeds ($12.1m net) through the issue of 13,324 shares of Series B convertible preferred stock (SBCPS) and 3,784,016 warrants exercisable at $4.05 per share. We believe the funds raised could sustain operations into early 2020. Each SBCPS is immediately convertible into 284 common shares. Assuming the full conversion of all SBCPS into common shares, the number of Atossa’s fully dilute
15 Jun 2018
Atossa Genetics - Atossa raises $13.4m in rights offering
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Atossa Genetics - Atossa raises $13.4m in rights offering
Atossa Therapeutics, Inc. (ATOS:NAS) | 0 0 0.0%
- Published:
15 Jun 2018 -
Author:
Pooya Hemami -
Pages:
5
Atossa’s previously announced rights offering closed on 30 May 2018, generating $13.3m in gross proceeds ($12.1m net) through the issue of 13,324 shares of Series B convertible preferred stock (SBCPS) and 3,784,016 warrants exercisable at $4.05 per share. We believe the funds raised could sustain operations into early 2020. Each SBCPS is immediately convertible into 284 common shares. Assuming the full conversion of all SBCPS into common shares, the number of Atossa’s fully dilute